I think the spike to 38 was a quick street reaction to what appeared to be a Myriad victory, but actually wasn't. The stock is going down. Their patent rights to the synthentic version DNA will not hold back competition on their main source of revenue, BRCA1 and BRCA2 testing.

However, the real victors are consumers worldwide. You will see a very quick drop in pricing for some of these genetic tests as competition comes to market in the near future. Myriad has been taking advantage of women for years. Their "list price" for BRCA testing is $4,000, which is outrageous given today's technology. Several companies have already said they will be bringing BRCA tests to market now for less than $1,000.